Maxcyte Share Price (NASDAQ: MXCT)

$1.4

▲

0.01

(0.72%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Maxcyte Stock chart to analyse performance

Maxcyte stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$1.38
Today's High:$1.41
$1.40
1.43%
Downside
Day's Volatility :2.13%
Upside
0.71%
52 Weeks Low:$1.26
52 Weeks High:$5.20
$1.40
10.0%
Downside
52 Weeks Volatility :75.77%
Upside
73.08%

Maxcyte Stock Returns

Period	Maxcyte Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-38.5%	3.6%	0.0%
6 Months	-59.24%	-7.7%	0.0%
1 Year	-66.01%	-12.6%	0.0%
3 Years	-74.5%	9.5%	-4.7%

Maxcyte Inc Key Stats

Check Maxcyte key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$1.39
Open	$1.41
Today's High	$1.41
Today's Low	$1.38
Market Capitalization	$148.2M
Today's Volume	$579.8K
52 Week High	$5.2
52 Week Low	$1.26
Revenue TTM	$35.8M
EBITDA	$-49.2M
Earnings Per Share (EPS)	$-0.42
Profit Margin	-125.22%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-21.74%

Stock Returns calculator for Maxcyte Stock including INR - Dollar returns

The Maxcyte stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Maxcyte investment value today

Current value as on today

₹39,514

Returns

₹60,486

(-60.49%)

Returns from Maxcyte Stock

₹65,770 (-65.77%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Maxcyte Stock

44%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Maxcyte Stock from India on INDmoney has increased by 44% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Maxcyte Inc

Name
Holdings %
Name
Holdings %
Cadian Capital Management LP
9.41%
BlackRock Inc
7.66%
Morgan Stanley - Brokerage Accounts
6.57%
Vanguard Group Inc
5.26%
Vitruvian Partners
4.73%
Mirabella Financial Services LLP
3.47%

Analyst Recommendation on Maxcyte Stock

Rating

Trend

Buy

92%Buy

7%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Maxcyte(by analysts ranked 0 to 5 stars)

Maxcyte Share Price Target

What analysts predicted

Upside of 377.14%

Target:

$6.68

Current:

$1.40

Maxcyte share price target is $6.68, a slight Upside of 377.14% compared to current price of $1.40 as per analysts' prediction.

Maxcyte Stock Insights

Price Movement
In the last 1 month, MXCT stock has moved down by -34.1%
Decreasing Revenue
Revenue is down for the last 2 quarters, 10.39M → 8.50M (in $), with an average decrease of 18.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -10.26M → -12.35M (in $), with an average decrease of 20.4% per quarter
MXCT vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 29.0% return, outperforming this stock by 96.8%
MXCT vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 163.5% return, outperforming this stock by 236.8%
Price to Sales
ForMXCT every $1 of sales, investors are willing to pay $4.1, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Maxcyte Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$21.6M	↑ 29.72%
Net Income	$-13.6M	↑ 53.07%
Net Profit Margin	-62.79%	↓ 9.58%

	FY20	Y/Y Change
Revenue	$26.2M	↑ 21.04%
Net Income	$-12.6M	↓ 6.88%
Net Profit Margin	-48.31%	↑ 14.48%

	FY21	Y/Y Change
Revenue	$33.9M	↑ 29.52%
Net Income	$-20.1M	↑ 59.2%
Net Profit Margin	-59.38%	↓ 11.07%

	FY22	Y/Y Change
Revenue	$44.3M	↑ 30.59%
Net Income	$-19.8M	↓ 1.72%
Net Profit Margin	-44.69%	↑ 14.69%

	FY23	Y/Y Change
Revenue	$41.3M	↓ 6.72%
Net Income	$-37.9M	↑ 91.71%
Net Profit Margin	-91.85%	↓ 47.16%

	FY24	Y/Y Change
Revenue	$38.6M	↓ 6.44%
Net Income	$-41.1M	↑ 8.26%
Net Profit Margin	-106.29%	↓ 14.44%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$11.3M	↓ 27.6%
Net Income	$-9.5M	↑ 80.52%
Net Profit Margin	-83.99%	↓ 50.31%

	Q2 FY24	Q/Q Change
Revenue	$10.4M	↓ 8.05%
Net Income	$-9.4M	↓ 1.59%
Net Profit Margin	-89.89%	↓ 5.9%

	Q3 FY24	Q/Q Change
Revenue	$8.2M	↓ 21.72%
Net Income	$-11.6M	↑ 23.27%
Net Profit Margin	-141.56%	↓ 51.67%

	Q4 FY24	Q/Q Change
Revenue	$8.7M	↑ 6.48%
Net Income	$-10.6M	↓ 8.31%
Net Profit Margin	-121.9%	↑ 19.66%

	Q1 FY25	Q/Q Change
Revenue	$10.4M	↑ 19.52%
Net Income	$-10.3M	↓ 3.17%
Net Profit Margin	-98.76%	↑ 23.14%

	Q2 FY25	Q/Q Change
Revenue	$8.5M	↓ 18.12%
Net Income	$-12.4M	↑ 20.43%
Net Profit Margin	-145.26%	↓ 46.5%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$19.1M	↑ 28.96%

	FY20	Y/Y Change
Profit	$23.4M	↑ 22.39%

	FY21	Y/Y Change
Profit	$30.2M	↑ 29.25%

	FY22	Y/Y Change
Profit	$39.2M	↑ 29.48%

	FY23	Y/Y Change
Profit	$36.5M	↓ 6.68%

	FY24	Y/Y Change
Profit	$31.5M	↓ 13.73%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$8.9M	↓ 31.92%

	Q2 FY24	Q/Q Change
Profit	$7.9M	↓ 10.87%

	Q3 FY24	Q/Q Change
Profit	$6.2M	↓ 21.13%

	Q4 FY24	Q/Q Change
Profit	$6.4M	↑ 2.82%

	Q1 FY25	Q/Q Change
Profit	$8.9M	↑ 38.69%

	Q2 FY25	Q/Q Change
Profit	$5.9M	↓ 33.57%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-8.8M	↓ 16.07%
Investing Cash Flow	$454.5K	↓ 111.86%
Financing Cash Flow	$12.3M	↑ 5328.04%

	FY20	Y/Y Change
Operating Cash Flow	$-8.8M	↓ 0.23%
Investing Cash Flow	$-16.6M	↓ 3747.52%
Financing Cash Flow	$28.9M	↑ 134.79%

	FY21	Y/Y Change
Operating Cash Flow	$-10.7M	↑ 21.61%
Investing Cash Flow	$-195.0M	↑ 1076.34%
Financing Cash Flow	$234.7M	↑ 712.05%

	FY22	Y/Y Change
Operating Cash Flow	$-14.8M	↑ 38.42%
Investing Cash Flow	$-24.8M	↓ 87.27%
Financing Cash Flow	$2.9M	↓ 98.77%

	FY23	Y/Y Change
Operating Cash Flow	$-21.7M	↑ 46.7%
Investing Cash Flow	$55.0M	↓ 321.5%
Financing Cash Flow	$2.1M	↓ 25.81%

	FY24	Y/Y Change
Operating Cash Flow	$-27.6M	↑ 27.32%
Investing Cash Flow	$6.9M	↓ 87.39%
Financing Cash Flow	$2.1M	↓ 4.06%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-10.6M	↓ 1176.09%
Investing Cash Flow	$-14.4M	↑ 247.79%
Financing Cash Flow	$703.0K	↑ 42.6%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-4.8M	↓ 54.24%
Investing Cash Flow	$19.4M	↓ 234.66%
Financing Cash Flow	$713.0K	↑ 1.42%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-4.4M	↓ 9.16%
Investing Cash Flow	$3.6M	↓ 81.39%
Financing Cash Flow	$228.0K	↓ 68.02%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-7.8M	↑ 78.11%
Investing Cash Flow	$-1.7M	↓ 146.15%
Financing Cash Flow	$412.0K	↑ 80.7%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-14.4M	↑ 84.26%
Investing Cash Flow	$9.5M	↓ 672.31%
Financing Cash Flow	$383.0K	↓ 7.04%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-9.9M	↓ 31.64%
Investing Cash Flow	$1.5M	↓ 83.86%
Financing Cash Flow	$154.0K	↓ 59.79%

Maxcyte Technicals Summary

Sell

Neutral

Buy

Maxcyte is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Maxcyte Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Maxcyte Inc	-32.52%	-59.24%	-66.01%	-74.5%	-86.71%
Medtronic Plc	3.87%	-1.59%	4.32%	4.82%	-13.69%
Edwards Lifesciences Corp.	2.55%	13.95%	18.33%	-9.73%	-5.31%
Boston Scientific Corp.	0.09%	0.6%	30.02%	157.38%	154.4%
Stryker Corporation	3.63%	-0.85%	8.87%	89.43%	97.71%
Abbott Laboratories	5.15%	-5.37%	15.72%	26.56%	24.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Maxcyte Inc	NA	NA	NA	-0.42	-0.22	-0.14	NA	1.79
Medtronic Plc	25.4	25.4	2.14	5.46	0.1	0.05	0.03	37.36
Edwards Lifesciences Corp.	34.03	34.03	4.85	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.95	62.95	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.54	51.54	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.64	16.64	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Maxcyte Inc	Buy	$148.2M	-86.71%	NA	-125.22%
Medtronic Plc	Buy	$118.0B	-13.69%	25.4	13.63%
Edwards Lifesciences Corp.	Buy	$47.8B	-5.31%	34.03	72.96%
Boston Scientific Corp.	Buy	$156.7B	154.4%	62.95	13.55%
Stryker Corporation	Buy	$149.0B	97.71%	51.54	12.25%
Abbott Laboratories	Buy	$230.9B	24.53%	16.64	32.43%

About Maxcyte Inc

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Organization	Maxcyte
Employees	114
CEO	Mr. Maher Masoud
Industry	Healthcare

Key Management of Maxcyte Inc

Name	Title
Mr. Maher Masoud	President, CEO & Executive Director
Mr. Douglas J. Swirsky CFA, CPA	Chief Financial Officer
Mr. Douglas Arthur Doerfler	Founder
Mr. Jay Gelfman	Senior Vice President of Operations
Mr. Ronald Evan Holtz CPA, Ph.D.	Executive Vice President of Administration
Mr. David Sandoval	Senior Vice President, General Counsel & Corporate Secretary
Mr. Jack Horgan	Vice President of Corporate Development
Ms. Ana-Paula Martins Fernandes	Senior Vice President of Global Sales
Ms. Jill Mayer	Senior Vice President of Human Resources
Dr. James Brady Ph.D.	Senior VP of Technical Applications & Customer Support

Important FAQs about investing in MXCT Stock from India :

What is Maxcyte share price today?

Maxcyte share price today is $1.40 as on August 30, 2025 at 1:29 am IST at the close of the market. Maxcyte share today touched a day high of $1.41 and a low of $1.38.

What is the 52 week high and 52 week low for Maxcyte share?

Maxcyte share touched a 52 week high of $5.20 and a 52 week low of $1.26. Maxcyte stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $1.40, lower by 73.08% versus the 52 week high.

How to invest in Maxcyte Stock (MXCT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Maxcyte on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Maxcyte Shares that will get you 1.0714 shares as per Maxcyte share price of $1.40 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Maxcyte Stock (MXCT) from India?

Indian investors can start investing in Maxcyte (MXCT) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Maxcyte stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Maxcyte share’s latest price of $1.40 as on August 30, 2025 at 1:29 am IST, you will get 7.1429 shares of Maxcyte. Learn more about fractional shares .

What are the returns that Maxcyte has given to Indian investors in the last 5 years?

Maxcyte stock has given -86.71% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?